US Investors Face No-ADR Direct Play as Afya Shares Slide 4.2%
Afya Limited shares fell 4.24% on November 19, 2026, offering US retail investors a rare direct-listing exposure to Brazilian medical education without ADR fees.

Key takeaways
- Afya shares fell 4.24% to close at $9.72, according to Nasdaq market data on November 19, 2026
- Afya reported R$985.2 million in Q3 revenue, a 6.1% year-over-year increase, per SEC filings on November 12, 2026
- Afya and Yduqs will combine in a deal where Afya shareholders own 69.0% of the merged firm, per merger documents on September 23, 2026
- The merger faces a contractual completion deadline of March 31, 2028, per company disclosures on November 12, 2026
American retail investors seeking direct exposure to South America's largest economy have very few choices that bypass the complex, fee-laden structures of international investing. One of those rare direct plays, Belo Horizonte-based medical education provider Afya Limited, saw its Nasdaq-listed shares fall 4.24% to close at $9.72 on November 19, 2026, according to Nasdaq market data. For US investors accustomed to trading Brazilian giants like Petrobras or Vale through American Depositary Receipts (ADRs), this company represents an unusual corporate structure: a Brazilian business with its primary listing in New York, meaning retail portfolios hold actual Class A common shares rather than depositary receipts.
This direct listing model eliminates the recurring depositary fees and foreign exchange conversion charges that often quietly erode the returns of ADR holders. Operating a network of medical schools across more than 20 states, Afya Brazil has built its business around the highly resilient demand for medical degrees in Latin America. According to the company's third-quarter earnings report filed with the Securities and Exchange Commission on November 12, 2026, quarterly revenue increased by 6.1% year-over-year to R$985.2 million, while net income rose to R$171.0 million. This growth was supported by a 3.9% increase in the average tuition ticket price for its undergraduate medical schools, which maintained full student occupancy during the period, according to the same November 12, 2026 SEC filing.
However, the recent downward pressure on the stock comes as the market digests a massive corporate transition. On September 23, 2026, Afya entered into a binding merger agreement with its domestic competitor Yduqs Participações S.A. Under the terms of the business combination, Afya will merge into Yduqs, with the latter surviving as the listed corporate entity. At the closing of the transaction, Afya's current shareholders are projected to own 69.0% of the combined group on a fully diluted basis, while Yduqs shareholders will hold the remaining 31.0%, according to the merger announcement on September 23, 2026. The deal aims to generate a projected R$2.2 billion in synergies, according to executives speaking at the company's annual investor day on October 20, 2026.
The transaction is far from a done deal, meaning investors face a waiting game. The merger is subject to approvals from the antitrust regulator, the Administrative Council for Economic Defense (CADE), as well as general shareholder votes from both companies. According to SEC filings from November 12, 2026, the contractual deadline to finalize the combination extends to March 31, 2028. Until the close, both educational platforms will continue to operate as independent competitors in the Brazilian market.
In your brokerage app
US retail investors can trade Afya Limited directly on Nasdaq, where it is listed in New York. The stock's recent close of $9.72 on November 19, 2026, puts it near its 52-week low of $9.66, down from a 52-week high of $16.16, according to Nasdaq historical data. Because these are primary Class A common shares rather than ADRs, investors can hold the stock in standard brokerage accounts without incurring foreign custody fees.
Analysis · NWX analysis desk
Which Brazil assets this touches
- AFYA — Named in this story.
- EWZ, NU, STNE, PAGS, IBOV — Big swings in U.S. tech stocks tend to spill into Brazil's fintechs listed in New York and into the broad Brazil fund, as global investors change how much risk they hold.
Technical picture · AFYA (AFYA)
AFYA (AFYA) closed at $9.72 on Nov 19, 2026, down 5.9% from five sessions earlier. The last close is below its 20-day average of $10.63 and below its 50-day average of $12.50. Since May 18, 2026 it has traded between $9.72 (low, Nov 19, 2026) and $15.27 (high, Jul 2, 2026).

| Last close | $9.72 | Closing price on Nov 19, 2026. |
|---|---|---|
| 5-session move | -5.9% | Change in the closing price over the last five trading days. |
| 20-day average | $10.63 | The average closing price of the last 20 trading days. |
| 50-day average | $12.50 | The average closing price of the last 50 trading days. |
| Period high | $15.27 | Highest price since May 18, 2026. |
| Period low | $9.72 | Lowest price since May 18, 2026. |
Related coverage
MercadoLibre Margin Shrinks to 6.3% on Brazil Expansion CostsMercadoLibre's Q3 2026 operating margin fell to 6.3% on November 5, 2026, as shipping and fintech expansion in Brazil offset robust 45.1% revenue growth.
Sigma Lithium Drops 3.55% on Nasdaq, Bypassing ADR RouteSigma Lithium shares fell 3.55% to $4.07 on Nasdaq on November 19, 2026, offering US retail investors a rare direct route to Brazil's mining sector without ADRs.
Sigma Lithium Shares Fall 3.55% in Rare Direct US Listing for BrazilSigma Lithium fell 3.55% to $4.07, showcasing the volatility of a rare direct Nasdaq listing of a Brazilian asset without ADR fees.